Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
CENTER OF IMMUNOLOGY - Romanian Academy - Coordinated by dr. Andrei Sulica, MD, PhD (1992 - 2000) - Coordinated by Lorelei Irina Brasoveanu, PhD (2000 – present) - Founded by Government Decision 46/ February 1992, as research center “with scientific and economical autonomy” that will function in the “Stefan S. Nicolau” Institute of Virology (1992) RESEARCH GROUPS / DOMAINS OF COMPETENCE (I) Research Group 1: « Tumor immunology and molecular biology » (coordinated by Dr. Lorelei I. Brasoveanu, Ph.D) Domains of competence: - Tumor immunology: flow-cytometry (antigen expression, apoptosis, cell cycle), immunological modulators, drug resistance, cell- and complement-mediated cytotoxicity; - Molecular biology: isolation of nucleic acids, gene expression by RTPCR or Real-time PCR; - Immunochemistry: antigen isolation and purification, biochemical characterization (SDS-PAGE, Western and dot blotting), ELISA, DDIA - Signal transduction RESEARCH GROUPS / DOMAINS OF COMPETENCE (II) Research Group 2: « Leukemias and chemoprevention » (coordinated by Dr. Viviana Roman, Ph.D) Domains of competence: - Immunochemistry: protein purification (chromatography, gel filtration, immunoprecipitation), SDS-PAGE, Western blotting, ELISA; - Immunology: flow-cytometry, regulation of apoptosis by nitric oxide, identification of its molecular targets, new therapies of leukemias, chemoprevention of cancer; - Molecular biology: isolation of nucleic acids, gene expression by RTPCR or Real-time PCR RESEARCH GROUPS / DOMAINS OF COMPETENCE (I) Research Group 3: « Cellular immunology » (Coordinated by Dr. Cecilia Galatiuc, Ph.D) Domains of competence: • - Cellular immunology : structural and functional characterization of Fc receptors (RFc) (IIIA, II , and ) on NK cells by flow-cytometry, NK cytotoxicity, proliferation assays, cytokines evaluation, apoptosis, molecular kinetics; • - Immunopathology : characterization of autoimmune diseases (idiopathic thrombocytopenic purpura, rheumatoid arthritis); effects of theraputical agents of these diseases. SCIENTIFIC DOMAINS OF INTEREST • • • • • • • • Biomarkers associated to human cancers (hematological cancers, breast, ovarian, glioma, colon, renal cancers, melanoma); Antigen/gene expression of tumor associated antigens, cell adhesion molecules, oncoproteins, molecules involved in angiogenesis; Signal transduction; Cancer stem cells; Effects of modulators (natural compounds, cytokines, drugs) on cell cycle progression, apoptosis, antigen and gene expression in tumor cells; drug resistance. In vitro studies of immunotherapeutical approaches in cancer; Expression and functional roles of complement regulatory molecules (CD59, CD55, CD46) and their impact in immunotherapy; NK cell function and regulation in normal and pathologic conditions RESEARCH UNITS and TECHNICAL FACILITIES (I) Cell cultures • • • • • • BioAir cell culture lamminary flow hood Revco and Hereus CO2 incubators Revco and Sanyo - 80 C° freezers liquid nitrogen recipients Beckman and Allegra refrigerated centrifuges Microscopes RESEARCH UNITS and TECHNICAL FACILITIES (II) Flow – cytometry: FACScan (Becton Dickinson) FACS Canto II (BD; RESEARCH UNITS and TECHNICAL FACILITIES (III) Molecular biology: - MJ Research DNA Thermo-Cycler and ChromoFour/ Real-Time PCR, - Biorad horizontal electrophoresis apparatus, - Biorad GelDoc UV/VIS Analyzer, - BioAir mini-hood, - Biosan thermoblock. Immunochemistry facilities: - Biorad and Hoeffer Scientific mini - and maxi - SDS-PAGE and Western blot apparatus; - Jensen dot blot apparatus; - Biorad IEF unit. OTHER: - Fluorometer/chemoluminometer (Victor 3, Tecan); - Elisa reader (Dynatex). - Tecan GENios unit (spectrophotometer/ spectrofluorimeter/ chemiluminometer); - Refrigerated centrifuges, microfuges. Research fields (I) • Tumor immunology: Cellular and molecular mechanisms of tumor progression; gene/ antigen expression of tumor associated molecules, cell adhesion molecules, oncoproteins, molecules involved in angiogenesis and their functional role; • Molecular biology: Biomarkers associated to human cancers (lymphoproliferative diseases, breast, ovarian, glioma, colon, renal cancers, melanoma); • Anticancer immunotherapy: in vitro studies of immunotherapeutical approaches in cancer; roles of complement regulatory molecules in tumor resistance with impact on immunotherapy); • Prevention/chemoprevention/multidrug resistance: effects of different modulators (biological active compounds, cytokines, drugs, oncolytical agents) on cell cycle progression, apoptosis, gene/ antigen expression of molecules involved and their functional roles in tumor cells; Research fields (II) • Cancer stem cells: human esophageal, colon tumours; • Cell signal transduction (Fc receptors; phosphorylated proteins); • Phenotipical and functional characterization of NK cells (the Fc g II and III A, a and m receptor mediated functional modulation of NK cells) in normal and pathologic conditions; • Monitoring and modulation of the immunological parameters in pathological conditions (Rheumatoid arthritis, Renal insufficiency, Idiopatic thrombocytopenic purpura) Effect of several therapeutical agents (AFI, IVIG) on lymphocyte subsets. • Ongoing Projects • PNII contract 42-173/2008 (Medical sciences, 2008-2011): “ Immunogenomical study of expression and functional roles of several cell adhesion molecules (CAM) associated to colorectal cancer” – as coordinator • PNII contract 62-078/2008 (Biotechnology, 2008-2011): „Biomarkers and chemopreventive agents in chronic lympho -proliferative diseases” – as coordinator • PNII contract 42-144/2008 (Medical sciences, 2008-2011): „Identification and characterization of a subpopulation of cells with tumor stem cell properties in hepatoma and esophageal cancers correlate with the mechanisms of resistance to treatment” – as partner • PNCDII contract 41-084/2007 (Medical sciences, 2007-2010): “Use of genetic markers for establishing targeted therapies for laryngeal and oropharyngeal human cancer” – as partner Reference Past Projects • • • • • • “Radiolabelled biomolecules in targeted treatment of cancer and inhibition of angiogenesis” (CEEX 26/2005, 2005-2008, partner) “Modulation of the expression of some biomarkers of tumor progression and correlation with resistance to chemotheray in breast and ovarian cancers” (CEEX 123/2006, 2006-2008, director) “Studies at cellular and molecular level regarding the biological activities of curcumin in order to evaluate its therapeutical potential” (CEEX 77/2006, 2006-2008, partner) “Study of the dynamics of expression of some genes involved in the control of cell cycle and apoptosis during ORL human cancer evolution” (CEEX 182/2006, 2006-2008,) “Modulation of apoptosis induced by mycotoxins in cell lines” (CEEX 82/2006, 2006-2008, partner) “Immunological and genotoxical blood assays in order toestablish the normal statistical values in Romanian adults” (CEEX 6/2005, 20052008, partner) Recent International Cooperations 2005-2010 • Institute Marie Curie, U-365, Paris, Franta (Prof. Jean-Pierre Kolb) • Centro di Riferimento Oncologico Aviano, Italia (Dr. Michele Maio; dr. Sandra Coral) • • Universitary Hospital of Siena, Italy (Dr. Michele Maio, dr. Ester Fonsatti) National Cancer Institute, University of Pittsburgh, USA (Prof. Theresa Whiteside, dr. Penelope Morrel, dr. Diana Metes, dr. Iulia Popescu) • Cellular Technology, Cleaveland, SUA (Dr. Ioana Moldovan, Dr. Iulia Popescu) • Institute of Pathophysiology, University of Viena, Austria (Prof. G. BoltzNiţulescu) NATIONAL COLLABORATIONS - Institute of Virology “Stefan S. Nicolau” (research facilities, common projects) - Institute of Oncology “Prof. dr. Alex. Trestioreanu”, Bucharest (BIOTECH, VIASAN, CNCSIS, CEEX) - Bucharest University, Faculty of Biology, Biochemistry Dept., Genetics Dept. (CERES, BIOTECH, COST, CNCSIS, CEEX) - Nuclear Physics Institute “Horia Hulubei” (CEEX) - University of Medicine “Gr.T. Popa” Jassy, Immunology Dept. (CNCSIS) - Clinical Hospital of Brain and Vascular Diseases “Vlad Voiculescu” CEEX)